Experimental bioengineering study demonstrates high-titer geranyllinalool synthesis in engineered yeast, indicating a scalable route for sustainable industrial biomanufacturing.
Background Acyclic diterpene alcohol, geranyllinalool (GL), is a natural insecticide and has diverse applications in cosmetics and pharmaceutical industries. The use of microbial cell factories for GL synthesis has been explored due to the non-sustainable nature of existing industrial manufacture methods. Results This study focused on three technical challenges encountered in GL cell factory construction in Saccharomyces cerevisiae , namely cellular supply of geranylgeranyl pyrophosphate, selection of GL synthases, and decisive factors for large-scale bioprocess development. With design for industrial uses in mind, a robust yet efficient terpenoids-synthesis enabling chassis strain was acquired. Next, a bifunctional prenyltransferase/terpene synthase enzyme (GLS12) of high efficiencies was identified and characterized in detail. Inclusion of GLS12 in the terpenoids chassis resulted in ~ 0.8 g/L of GL synthesis in shake-flask cultivations. Scale-up study was completed with ~ 9 g/L GL produced in a 10-L bioreactor in 96 h by fed-batch fermentation, the highest reported titer to date. Conclusions A high-performance yeast strain was engineered to enable efficient GL production using ethanol as the primary carbon source. This work demonstrated the potential of microbial GL fermentation for industrial uses.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: